

**DESCRIPTION**

<b>Source</b>	Mouse myeloma cell line, NS0-derived human PDGF-DD protein Ser250-Arg370 Accession # Q9GZP0.1
<b>N-terminal Sequence Analysis</b>	Ser250
<b>Structure / Form</b>	Disulfide-linked homodimer
<b>Predicted Molecular Mass</b>	14 kDa (monomer)

**SPECIFICATIONS**

<b>SDS-PAGE</b>	19 kDa, reducing conditions
<b>Activity</b>	Measured in a cell proliferation assay using NR6R-3T3 mouse fibroblast cells. Raines, E.W. <i>et al.</i> (1985) <i>Methods Enzymol.</i> <b>109</b> :749. The ED <sub>50</sub> for this effect is 15-75 ng/mL in a fluorometric assay using the redox sensitive dye, Resazurin (Catalog # AR002) and 2-5 ng/mL when measured by <sup>3</sup> H-thymidine incorporation.
<b>Endotoxin Level</b>	<0.01 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 100 µg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

The platelet-derived growth factor (PDGF) family consists of four disulfide-linked homodimers and one heterodimer (PDGF-AB). These proteins regulate diverse cellular functions through interactions with PDGF R $\alpha$  and R $\beta$  (1, 2). Mature PDGF-DD associates with PDGF R $\beta$  and triggers signaling through PDGF R $\beta$  homodimers and PDGF R $\alpha$ / $\beta$  heterodimers (3 - 5). The human PDGF-DD cDNA encodes a 370 amino acid (aa) precursor that includes a 23 aa signal sequence, one CUB domain, and one PDGF/VEGF domain (3, 4). The PDGF/VEGF domain shares 27 - 35% aa sequence identity with the corresponding regions of other PDGF family members. Human PDGF-DD shares 87% aa sequence identity with mouse and rat PDGF-DD. PDGF-DD is secreted as a 100 kDa latent homodimer which is activated by proteolysis to release a 35 kDa bioactive protein containing the PDGF/VEGF homology domain (3, 4, 6, 7). A splice variant of PDGF-DD has a 6 aa deletion near the N-terminus. A 72 aa deletion within the PDGF/VEGF domain generates an inactive protein in mouse but has not been detected in human (8). PDGF-DD is widely expressed in embryonic and adult tissues (3, 9, 10), and PDGF R $\beta$  is expressed in a generally complementary pattern (9, 11, 12). PDGF-DD functions as a growth factor for renal artery smooth muscle cells and lens epithelial cells, and as a macrophage chemoattractant (5, 9 - 11). PDGF-DD is overexpressed in and contributes to several disease states, including renal and hepatic fibrosis, mesangial proliferative glomerulopathy, pulmonary lymphoid infiltration, and many cancers (6, 11 - 15). PDGF-DD functions in both paracrine and autocrine manners (6, 7, 14).

**References:**

1. Reigstad, L.J. *et al.* (2005) *FEBS J.* **272**:5723.
2. Fredriksson, L. *et al.* (2004) *Cytokine Growth Factor Rev.* **15**:197.
3. LaRochelle, W.J. *et al.* (2001) *Nat. Cell Biol.* **3**:517.
4. Bergsten, E. *et al.* (2001) *Nat. Cell Biol.* **3**:512.
5. Uutela, M. *et al.* (2004) *Blood* **104**:3198.
6. Ustach, C.V. and H-R.C. Kim (2005) *Mol. Cell. Biol.* **25**:6279.
7. Ustach, C.V. *et al.* (2004) *Canc. Res.* **64**:1722.
8. Zhuo, Y. *et al.* (2003) *Biochem. Biophys. Res. Commun.* **308**:126.
9. Changsirikulchai, S. *et al.* (2002) *Kid. Int.* **62**:2043.
10. Ray, S. *et al.* (2005) *J. Biol. Chem.* **280**:8494.
11. Hudkins, K.L. *et al.* (2004) *J. Am. Soc. Nephrol.* **15**:286.
12. Lokker, N.A. *et al.* (2002) *Canc. Res.* **62**:3729.
13. Taneda, S. *et al.* (2003) *J. Am. Soc. Nephrol.* **14**:2544.
14. LaRochelle, W.J. *et al.* (2002) *Canc. Res.* **62**:2468.
15. Xu, L. *et al.* (2005) *Canc. Res.* **65**:5711.